{"organizations": [], "uuid": "2ef38c075643bebd7960aca385af4a88f682e61e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biotime-announces-cash-sale-of-asc/brief-biotime-announces-cash-sale-of-ascendance-biotechnology-idUSFWN1R909S", "country": "US", "domain_rank": 408, "title": "BRIEF-BioTime Announces Cash Sale Of Ascendance Biotechnology", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T14:06:00.000+03:00", "replies_count": 0, "uuid": "2ef38c075643bebd7960aca385af4a88f682e61e"}, "author": "", "url": "https://www.reuters.com/article/brief-biotime-announces-cash-sale-of-asc/brief-biotime-announces-cash-sale-of-ascendance-biotechnology-idUSFWN1R909S", "ord_in_thread": 0, "title": "BRIEF-BioTime Announces Cash Sale Of Ascendance Biotechnology", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-biotime announces cash sale of ascendance biotechnology reuters", "sentiment": "negative"}, {"name": "ascendance biotechnology", "sentiment": "negative"}, {"name": "biotime inc", "sentiment": "none"}, {"name": "biotime inc", "sentiment": "none"}, {"name": "agex", "sentiment": "none"}, {"name": "biotime", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Biotime Inc:\n* BIOTIME ANNOUNCES CASH SALE OF ASCENDANCE BIOTECHNOLOGY * BIOTIME INC - BIOTIME SUBSIDIARY, AGEX, TO RECEIVE UP TO $3.5 MILLION IN CASH\n* BIOTIME INC - AGEX RECEIVED APPROXIMATELY $3.2 MILLION UPON CLOSE OF ACQUISITION FOR ITS INTEREST IN ASCENDANCE\n* BIOTIME - UPON TERMINATION OF ESCROW, AGEX WILL RECEIVE REMAINDER OF CONSIDERATION SUBJECT TO DEDUCTIONS OF LIABILITIES AND/OR EXPENSES FROM ESCROW Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-03-27T14:06:00.000+03:00", "crawled": "2018-03-27T14:22:17.009+03:00", "highlightTitle": ""}